# Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

> **NCT00324116** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 81 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** pegaptanib sodium (Macugen)

## Key facts

- **NCT ID:** NCT00324116
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2010-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324116, "Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00324116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*